Drug-drug interactions in the intensive care unit: Do they really matter?

Delphine Vanham(Cliniques Universitaires Saint-Luc), Barbara Sneyers(Cliniques Universitaires Saint-Luc), Xavier Wittebole(Cliniques Universitaires Saint-Luc), Anne Spinewine(CHU Dinant Godinne UCL Namur), D. Wouters(Cliniques Universitaires Saint-Luc), Ph. Hantson(Cliniques Universitaires Saint-Luc)
Journal of Critical Care
October 8, 2016
10.1016/j.jcrc.2016.09.014
Cited by 44

Related Papers

High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure
|New England Journal of Medicine|2015|2.4k
Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017
|JAMA|2020|1k
Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis
|JAMA|2013|797
A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens
|Virulence|2013|599
Sepsis in Intensive Care Unit Patients: Worldwide Data From the Intensive Care over Nations Audit
|Open Forum Infectious Diseases|2018|530